Optimality, Future and Terminal Costs: Comment on “Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran”

Trastuzumab Therapy ◽

Author Correction to: Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy

PharmacoEconomics ◽

10.1007/s40273-018-0634-5 ◽

2018 ◽

Vol 36 (4) ◽

pp. 505-505

Author(s):

Amir Ansaripour ◽

Carin A. Uyl-de Groot ◽

W. Ken Redekop

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Scenario Analysis ◽

Treatment Strategy ◽

Her2 Positive ◽

Adjuvant Trastuzumab ◽

Trastuzumab Therapy ◽

Optimal Treatment Strategy ◽

Trastuzumab use at relapse after adjuvant trastuzumab therapy in HER2-positive breast cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.575 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. 575-575 ◽

Cited By ~ 1

Author(s):

I. Lang ◽

R. Bell ◽

F. Feng ◽

R. I. Lopez ◽

J. Jassem ◽

...

Keyword(s):

Breast Cancer ◽

Her2 Positive ◽

Adjuvant Trastuzumab ◽

Trastuzumab Therapy ◽

Management of metastatic HER2-positive breast cancer progression after adjuvant trastuzumab therapy – current evidence and future trends

Expert Opinion on Investigational Drugs ◽

10.1517/13543781003730135 ◽

2010 ◽

Vol 19 (sup1) ◽

pp. S31-S39 ◽

Cited By ~ 4

Author(s):

Otto Metzger-Filho ◽

Tushar Vora ◽

Ahmad Awada

Keyword(s):

Breast Cancer ◽

Cancer Progression ◽

Breast Cancer Progression ◽

Current Evidence ◽

Future Trends ◽

Her2 Positive ◽

Adjuvant Trastuzumab ◽

Trastuzumab Therapy ◽

Adjuvant Trastuzumab Therapy In Her2-Positive Breast Cancer Patients: A Meta-Analysis Of Published Randomized Trials

Value in Health ◽

10.1016/j.jval.2013.03.622 ◽

2013 ◽

Vol 16 (3) ◽

pp. A128

Author(s):

Y. Xia ◽

B. Bian ◽

E. Costea ◽

C.M. Kelton ◽

J.J. Guo

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Randomized Trials ◽

Meta Analysis ◽

Breast Cancer Patients ◽

Her2 Positive ◽

Adjuvant Trastuzumab ◽

Trastuzumab Therapy ◽

PCN61 COST-EFFECTIVENESS OF 1-YEAR ADJUVANT TRASTUZUMAB THERAPY FOR EARLY STAGE OF HER2-POSITIVE BREAST CANCER

Value in Health ◽

10.1016/j.jval.2011.02.916 ◽

2011 ◽

Vol 14 (3) ◽

pp. A165

Author(s):

T.T.T. Nguyen ◽

R. Yagudina ◽

A.U. Kulikov

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Early Stage ◽

Her2 Positive ◽

Adjuvant Trastuzumab ◽

Trastuzumab Therapy ◽

Cost-Effectiveness Analysis of 1-Year Adjuvant Trastuzumab Therapy of Early-Stage Her2-Positive Breast Cancer

Value in Health ◽

10.1016/j.jval.2014.08.107 ◽

2014 ◽

Vol 17 (7) ◽

pp. A735 ◽

Cited By ~ 1

Author(s):

Nguyen TTC ◽

Nguyen TTT

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Early Stage ◽

Cost Effectiveness Analysis ◽

Her2 Positive ◽

Adjuvant Trastuzumab ◽

Trastuzumab Therapy ◽

Effectiveness Analysis ◽

Response to ‘Comment on ‘‘Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy”’

PharmacoEconomics ◽

10.1007/s40273-018-0620-y ◽

2018 ◽

Vol 36 (3) ◽

pp. 381-382

Author(s):

Amir Ansaripour ◽

Carin A. Uyl-de Groot ◽

W. Ken Redekop

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Scenario Analysis ◽

Treatment Strategy ◽

Her2 Positive ◽

Adjuvant Trastuzumab ◽

Trastuzumab Therapy ◽

Optimal Treatment Strategy ◽

Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy

PharmacoEconomics ◽

10.1007/s40273-017-0557-6 ◽

2017 ◽

Vol 36 (1) ◽

pp. 91-103 ◽

Cited By ~ 11

Author(s):

Amir Ansaripour ◽

Carin A. Uyl-de Groot ◽

W. Ken Redekop

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Scenario Analysis ◽

Treatment Strategy ◽

Her2 Positive ◽

Adjuvant Trastuzumab ◽

Trastuzumab Therapy ◽

Optimal Treatment Strategy ◽

Adjuvant Trastuzumab Therapy for HER2-Positive Breast Cancer

Clinical Breast Cancer ◽

10.3816/cbc.2008.n.037 ◽

2008 ◽

Vol 8 (4) ◽

pp. 324-333 ◽

Cited By ~ 48

Author(s):

Mohammad Jahanzeb

Keyword(s):

Breast Cancer ◽

Her2 Positive ◽

Adjuvant Trastuzumab ◽

Trastuzumab Therapy ◽

Faculty Opinions recommendation of 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718043513.793482079 ◽

2013 ◽

Author(s):

Ana Maria Gonzalez-Angulo

Keyword(s):

Breast Cancer ◽

Randomised Controlled Trial ◽

Controlled Trial ◽

Her2 Positive ◽

Open Label ◽

Adjuvant Trastuzumab ◽

Randomised Controlled ◽